Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This is a clinical research study to evaluate if chemotherapy in the experimental arm (E)
results in a better outcome compared to patients in the standard of care arm (C).
2:1 randomization to experimental arm (E) or standard arm (C). In arm E, treatment of
dual-agent chemotherapy will be selected based on RRM1 and ERCC1 expression at the protein
level. In arm C, treatment of dual-agent chemotherapy will be gemcitabine/carboplatin, i.e.,
standard of care.
Phase:
Phase 3
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute